Through a collaboration with the University of Bristol, we develop dynamic, deterministic models of hepatitis C and HIV transmission among injecting drug users (IDUs), in order to guide policymaking surrounding hepatitis C and HIV treatment and prevention. Our models have been used to: examine the impact1 2 and cost-effectiveness3 of using HIV or HCV antiviral treatment for IDUs as a means of primary prevention of HIV/HCV among the IDU population; explore trends in HIV and HCV prevalence among IDUs in different settings3 4 5 6; determine the current and future impact of prevention interventions such as opiate substitution therapy and needle and syringe programmes7 2 8; evaluate the cost-effectiveness of interventions to increase HCV testing among IDUs9 or the levels of syringe distribution10 11 12.
- Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S., Goldberg, D., and Hickman, M. 2011. Can Antiviral Therapy for Hepatitis C Reduce the Prevalence of HCV Among Injecting Drug User Populations? A Modelling Analysis of its Prevention Utility. J Hep. 54(6):1137-44.
- Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C., Hickman, M. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285-301.
- Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S., Goldberg, D., and Hickman, M. 2012. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology 55(1):49-57. Vickerman, P., Martin , N.K., and M Hickman. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings—Implications for intervention impact. Drug Alcohol Depend. (2011), doi:10.1016/j.drugalcdep.2011.10.032.
- Vickerman, P. Hickman, M., May, M., Kretzschmar, M., Wiessing L. (2010) Can HCV prevalence be used as a measure of injection-related HIV-risk in populations of injecting drug users? An ecological analysis. Addiction 105(2):311-8.
- Vickerman, P., Platt, L., Hawkes, S. (2009) Modelling the transmission of HIV and HCV amongst injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. STI 85 supp 2: ii23-30.
- Vickerman P., Hickman M., Judd A. (2007) Modelling the impact of hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 36: 396-405.
- Vickerman P., Martin, N.K., and Hickman, M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic scenarios. (submitted).
- Vickerman P., Hickman M., Rhodes T., Watts C. (2006) Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug user. JAIDS 42: 355-361.
- Martin, N.K., Miners, A., and Vickerman, P. 2012. Assessing the cost-effectiveness of interventions aimed at promoting and offering hepatitis C testing to injecting drug users: An economic modeling report. National Instititue for Clinical Excellence (NICE) public health report. (In publication).
- Guinness, L., Vickerman, P., Quayyum, Z., Foss, A., Watts, C. et al. (2009) The cost-effectiveness of intervening early and consistently: harm reduction in Bangladesh. Addiction 105(2):319-28
- Vickerman, P., Kumaranyake, L., Balakireva, O., Guinness, L., Artyukh, O., Semikop, T., Yaremenko, O., Watts, C. (2006) The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. STD 33 (10) supplement: S89-S102
- Kumaranyake, L., Vickerman, P., Walker, D., Samoshkin, S., Romantsov, V., Zviagin, V., Emelyanova, Z., Watts, C. (2004) The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction 99: 1565-1576